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Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is characterized by ventricular arrhythmias and ﬁbrofatty
replacement of the right ventricular (RV) myocardium.
Although the RV is the predominant chamber involved, left
ventricular (LV) involvement has also been documented.1–4
Electrophysiological correlations of histopathologic ﬁndings
in nonischemic cardiomyopathy, and especially in ARVC,
are limited.5 We report a case of ARVC that presented with
ventricular tachycardia (VT) and diffuse ﬁbrofatty involve-
ment of both the RV and LV. A detailed analysis of the
electrophysiological, cardiac imaging, and pathologic ﬁnd-
ings was performed, providing insights into the electro-
achitecture of the myocardium and electrical manifestations
of the pathologic ﬁndings.
Case report
A 57-year-old female with a family history of ventricular
arrhythmias and ARVC was implanted with a dual-chamber
implantable cardioverter deﬁbrillator. Because of recurrent
VTs and deﬁbrillator shocks, she underwent electrophysio-
logical study and epicardial and endocardial catheter ablation
of the VT in September 2011. A total of 2815 epicardial and
1110 endocardial voltage points were obtained. The epicar-
dial electroanatomic map demonstrated extensive scarring of
the RV free wall and LV anterior wall. The endocardial map
showed extensive scarring of the interventricular septum
(IVS) and right ventricular outﬂow tract (RVOT). Late
potentials, particularly on the RV anterior free wall, were
noted on the epicardium. A slow monomorphic VT (leftKEYWORDS Arrhythmogenic right ventricular cardiomyopathy; Cardiac MRI;
Catheter ablation; Pathology; Ventricular tachycardia
ABBREVIATIONS ARVC ¼ arrhythmogenic right ventricular cardio-
myopathy; EAM ¼ electroanatomic mapping; EGM ¼ electrogram;
IVS ¼ interventricular septum; LV ¼ left ventricle; MRI ¼ magnetic
resonance imaging; RV ¼ right ventricle; RVOT ¼ right ventricular
outflow tract; VT ¼ ventricular tachycardia
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length 580 to 750 milliseconds) was induced (Figure 1) and
terminated during ablation in the RVOT. Rather than
targeting the extensive low-voltage areas identiﬁed as “scar”
on both the LV and RV by electroanatomic mapping, speciﬁc
sites with late potential and late fractionated electrograms
(EGMs) were targeted, particularly on the epicardial and
endocardial aspect of the RVOT. The patient underwent
orthotopic heart transplantation in September of 2014 for
progressive heart failure. Ex vivo cardiac magnetic reso-
nance imaging (MRI) was performed on the explanted heart
along with a comparative investigation of the electrophysio-
logical, pathologic, and imaging ﬁndings. The explanted
heart demonstrated marked inﬁltration of ﬁbrofatty tissue,
with areas of complete transmural myocardial replacement.
The pathological ﬁndings correlated well with cardiac MRI
results, but MRI could not distinguish between epicardial fat
and ﬁbrofatty replacement of the LV (Figure 1). EGMs from
multiple regions with very low voltage (o0.5 mV) and
border zones (0.5 to 1.5 mV), as well as viable myocardium
on EAM were analyzed and the histologic ﬁndings at these
sites evaluated (Figures 2 and 3). The patient remained
arrhythmia free postablation and underwent heart trans-
plantation for heart failure.Discussion
ARVC is characterized by RV myocyte loss and ﬁbrofatty
tissue replacement, and it predisposes patients to life-
threatening ventricular arrhythmias.6 Biventricular and
left-dominant forms of the disease, although less common,
are increasingly recognized.1–4 In this case, the patient had
experienced multiple episodes of syncope and had shown
evidence of RV dilatation on an echocardiogram as early as
1993 in her native country, but she was not diagnosed till
2009, when she presented with syncope from VT, family
history of ARVC, RV dilatation on echocardiogram, and
presence of epsilon waves on electrocardiograms. At the
time of transplantation, notably thick, diffuse ﬁbrofatty
tissue inﬁltration of both the RV and LV was observed. The
degree of inﬁltration was so extensive that, on in vivo MRIpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Local abnormal ventricular activities and late
potentials on electroanatomic mappings correlate
with inhomogeneous areas of surviving
myocardium admixed with ﬁbrofatty tissue on
histopathology. Only fat was observed in areas
denoted by low-voltage (o0.5 mV), short-duration
electrograms on the electroanatomic map.
 The site of successful ablation of ventricular
tachycardia was in very close proximity to a
heterogenous substrate consisting of surviving
myocardium and ﬁbrofatty tissue on
histopathology.
 This case of arrhythmogenic right ventricular
cardiomyopathy demonstrated diffuse thick
ﬁbrofatty inﬁltration of both ventricles, including
the interventricular septum, with irregular areas of
ﬁbrofatty tissue noted in most of these regions.
Heart Rhythm Case Reports, Vol 2, No 1, January 201648results, it was difﬁcult to distinguish between myocardial
ﬁbrofatty inﬁltration and epicardial fat. The ﬁbrofatty
tissue covering the LV had the same thickness as the viableA
C
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Figure 1 A: A 12-lead electrocardiogram showing sinus rhythm. The electrocar
and low voltage, given epicardial-to-endocardial ﬁbrofatty inﬁltration. B: Ventric
consistent with a right ventricular outﬂow tract origin. C: Comparison of ex vivo
section (left lower panel). Thick diffuse fatty tissue around the right ventricle and l
ventricles, including in the interventricular septum (IVS) (blue square). D: Fatty inﬁ
sections demonstrates an area with surviving myocardium surrounded by ﬁbrofatty
the gross and histopathologic sections.)LV myocardium, and the entire RV myocardium had
been replaced. Further, ﬁbrofatty inﬁltration into the
IVS was demonstrated on MRI and histologic ﬁndings
(Figure 1).
The ﬁndings on histopathology closely matched those of
MRI performed ex vivo (Figure1C), supporting the notion
that MRI remains an important tool for evaluating ﬁbrofatty
inﬁltration in patients with ARVC before electrophysiolog-
ical study.7,8 Although this patient did not undergo heart
transplantation immediately after VT ablation, the EAM and
histopathology ﬁndings correlated well, as suggested by a
recent study showing that the majority of ARVC patients
have similar electroanatomic maps at mean of 57 months
apart.9 Of note, the ﬁbrofatty inﬁltration in this case was not
homogenous. In addition to “linear” ﬁbrofatty layers in the
IVS (Figure 1), very localized rounded inﬁltrations in the LV
anteroapex (Figure 2) and inﬁltrating layers in the RVOT
(Figure 3) were observed. This heterogeneous inﬁltration, or
tissue anisotropy, has important implications for arrhythmo-
genesis, serving as the substrate for arrhythmias and sites of
reentry.
It has been previously reported that the presence of
epicardial fat can confound quantiﬁcation of electrophysio-
logical scar on EAM, as both myocardial ﬁbrosis and fat areB
diogram in sinus rhythm demonstrates epsilon waves in V1-V5 (red arrow),
ular tachycardia morphology observed during electrophysiological study is
cardiac magnetic resonance image (left upper panel) and gross pathologic
eft ventricle was observed. There is evidence of ﬁbrofatty inﬁltration in both
ltration in the IVS on the gross (left panel) and histopathologic (right panel)
inﬁltration. (Asterisk, arrow, and arrowhead point to similar regions between
A B
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Figure 2 Correlation of electroanatomic mapping with gross pathology A: A gross section of the left ventricle (LV) demonstrates surviving myocardium in
the LV anteroapex (upper panel) and apex covered with ﬁbrofatty tissue (lower panel). B: Superimposed right ventricular (RV) endocardial and epicardial
electroanatomic mappings (EAMs). The electrograms (EGMs) from corresponding sites in panel A are shown. A fractionated EGM with evidence of a late
potential is observed in the border-zone region between surviving myocardium and fat. The surviving myocardium shows normal voltage, while fat demonstrates
very low-voltage EGMs. C:Histopathologic ﬁndings from the gross section shown in panel A and the corresponding sites on EAMs and EGMs from panel B are
shown: (1) Signiﬁcant ﬁbrofatty inﬁltration with surviving myocardium (FFSM) was seen in an area of fractionated EGMwith late potentials; (2) predominantly
viable myocardium with some interstitial ﬁbrosis was seen in an area of normal voltage; and (3) epicardial fat was seen in an area of low-voltage, short-
duration EGM.
49Watanabe et al Arrhythmogenic Substrate of ARVCrepresented by low-voltage signals.8,10–12 In animal models,
surviving islands of myocardium within scars of healed
myocardial infarcts exhibit more fractionation and longer
duration EGMs compared to fatty tissue overlying normal
myocardium.12 In this case, extensive low-voltage areas
were observed on the ventricular epicardium on EAM
(Figures 2 and 3), but based on but on histopathology,
represented predominantly fat. Fractionation and late poten-
tials were observed in the RVOT and LV anteroapex locally
(Figures 2 and 3). On histopathologic examination, in areas
close to these ablation sites, a heterogeneous substrate
consisting of ﬁbrofatty tissue and surviving myocytes was
seen. Ablation from both the epicardium and endocardium in
these regions created areas of transmural ﬁbrosis (Figure 3),
ranging from 600 μm to 1.5 mm in depth, including in the
region of VT termination, Surviving islands of myocardium
within the ﬁbrofatty tissue served as the substrate for VT,
whereas low-voltage areas without late potentials or fractio-
nation were not important targets for ablation. In this patient,
given the presence of histopathologic conﬁrmation, weanalyzed the voltage and duration of 25 EGMs from areas
of pure ﬁbrofatty tissue (FFSM), ﬁbrofatty inﬁltration with
surviving myocardium, and viable myocardial regions without
ﬁbrosis or fat (Figure 3C). Areas of thick ﬁbrofatty inﬁltration
with little viable myocardium exhibited low-voltage and short-
duration EGMs (voltage 0.17  0.14mV, duration 59  20
milliseconds, mean  SD). On histopathology areas of
surviving myocardium admixed with ﬁbrofatty tissue, exhib-
ited low-voltage and long-duration EGMs (voltage 0.30 
0.12mV, duration 109  28 milliseconds, mean  SD), and
border-zone regions with surviving myocytes exhibited long-
duration EGMs (voltage 0.89  0.39 mV, duration 89  31
milliseconds, mean +/- SD). Normal myocardium demon-
strated high-voltage, short-duration EGMs (voltage 2.78 
1.47 mV, duration 69  16 milliseconds). These ﬁndings
conﬁrm that islands of surviving myocardium within ﬁbrofatty
tissue of ARVC, similar to myocardia infarcts, are electrically
active and represented by low-voltage, long-duration EGMs.
Percutaneous epicardial mapping has become an impor-
tant strategy for ablation of VT in ARVC cases.13–15 Rather
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Figure 3 Correlation of electroanatomic mapping with histopathologic ﬁndings in the right ventricular outﬂow tract (RVOT). A: Electrograms (EGMs) from
an area of low voltage below the pulmonic valve and 2 sites on the epicardium (Epi) and endocardium (Endo) prior to ablation are shown. B:Gross section (upper
panel) and corresponding histopathologic ﬁndings (lower panel) of an ablated region in the RVOT. The red arrow points to the ablation site, and the black arrows
demonstrate corresponding sites between gross and histologic sections. The corresponding EGMs in panel A from both epicardium and endocardium (red arrow)
prior to ablation demonstrate fractionation and late potentials. After ablation, this site shows a transmural ﬁbrotic lesion. The asterisk demonstrates fat below the
pulmonic valve on histologic ﬁndings (region 1). C: Analysis of a total of 100 EGMs (25 from each region) of corresponding sites on histologic ﬁndings and
electroanatomic mappings (EAMs). Pure fatty or ﬁbrofatty replacement had low-voltage, short-duration EGMs. Sites near areas of normal voltage consisting of
surviving myocardium surrounded by ﬁbrofatty inﬁltrations exhibited low-voltage but long-duration EGMs. Areas with border-zone EGMs (voltage between 0.5
and 1.5 mV) often also contained fatty or ﬁbrofatty inﬁltration with surviving islands of myocardium and exhibited EGMs of long duration. FFSM = ﬁbrofatty
inﬁltration admixed with surviving myocardium; BZ = border zones; FAT = fatty tissue without surviving myocytes; viable = areas of normal myocardium.
Heart Rhythm Case Reports, Vol 2, No 1, January 201650than targeting all low-voltage areas, which are extensive and
likely represent fat, it is important to target fractionated and
late potential EGMs of long duration that represent areas of
surviving myocardium within ﬁbrous tissue.Conclusion
This case report sheds light upon the electrical manifesta-
tions that serve as the histopathologic signature of arrhyth-
mias in ARVC, in addition to emphasizing important
limitations faced in ablation of these cases, such as thickness
of fatty tissue and inﬁltration into the IVS. It conﬁrms that
islands of surviving myocardium admixed with ﬁbrofatty
tissue of ARVC are electrically active; create tissue aniso-
tropy; are represented by low-voltage, long-duration EGMs;
and serve as the substrate for VT.Acknowledgments
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